Innoviva, Inc. (INVA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$21.13-0.98%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Total revenue grows to at least $440 million in FY26: FY25 revenue $296.7M vs trip <$296M; FY26 guide $150M vs target $440M.
Innoviva grows revenue steadily with royalties and product sales. Net income rose from $20M to $186M in recent quarters. The company plans to launch NUZOLVENCE in late 2026. Profit margins remain stable near $38M operating income.
Revenue growth could slow below 10% if royalties weaken. Profit margins might compress with higher commercial costs. The new product launch may face delays or weak sales.
The price is about 49% below our fair value near $43. Analysts expect 57% revenue growth, which we view as optimistic but justified given recent beats and growth.
Breaks if: Net income falls below $20 million in any quarter
Breaks if: NUZOLVENCE launch delayed beyond 2026 or fails to gain market traction
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a stable growth opportunity in the healthcare sector. The current thesis is supported by strong recent financial performance and management's focus on achieving key sales targets.
The market currently prices INVA as a cheap option compared to its peers, reflecting a low expectations gap. This suggests that investors may not fully account for the company's potential growth despite its recent strong results.
Fundamentals are likely to remain stable, with management on track to meet their sales targets. However, there is a moderate risk due to the potential for earnings misses, given the company's history in a high-miss-rate industry.
The thesis hinges on management's ability to deliver on their sales targets and the overall performance of the healthcare sector. Key factors include guidance updates and the performance of sector bellwethers like VRTX and REGN.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss has negatively impacted the outlook. This miss raises concerns about the company's ability to meet revenue targets.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Prepare for and execute the commercialization of NUZOLVENCE, an FDA-approved oral treatment for uncomplicated urogenital gonorrhea, in H2 2026.
Stated as a priority in 3 of last 3 quarters. NUZOLVENCE received FDA approval in December 2025 and management has consistently stated plans to commercialize it in the second half of 2026. No revenue yet reported from NUZOLVENCE, so delivery is pending but on track.
“NUZOLVENCE approved by FDA; plans to commercialize in second half of 2026.”
“Company remains on track to make NUZOLVENCE available to patients in second half of 2026.”
“FDA approval of NUZOLVENCE received in December 2025; plans to commercialize in 2026.”
Breaks if: Total revenue falls below $296 million in FY25
Continue driving revenue growth through resilient royalties and expanding IST U.S. net product sales.
Overall, INVA's position appears solid for the next 1 to 3 years, contingent on effective execution and sector dynamics. Not investment advice.